...
首页> 外文期刊>Experimental Biology and Medicine: Journal of the Society for Experimental Biology and Medicine >Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2
【24h】

Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2

机译:血管紧张素II通过AT1R和ERK1 / 2增加人主动脉平滑肌细胞中基质金属蛋白酶2的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Increased levels of angiotensin II (Ang II) and activated matrix metalloproteinase 2 (MMP-2) produced by human aortic smooth muscle cells (human ASMCs) have recently been implicated in the pathogenesis of thoracic aortic aneurysm (TAA). Additionally, angiotensin II type 1 receptor (AT1R)-mediated extracellular signal-regulated kinase (ERK)1/2 activation contributes to TAA development in Marfan Syndrome. However, there is scant data regarding the relationship between Ang II and MMP-2 expression in human ASMCs. Therefore, we investigated the effect of Ang II on MMP-2 expression in human ASMCs and used Western blotting to identify the Ang II receptors and intracellular signaling pathways involved. Reverse transcription polymerase chain reaction (RT-PCR) and immunofluorescence data demonstrated that Ang II receptors were expressed on human ASMCs. Additionally, Ang II increased the expression of Ang II type 2 receptor (AT2R) but not AT1R at both the transcriptional and translational levels. Furthermore, Western blotting showed that Ang II increased MMP-2 expression in human ASMCs in a dose- and time-dependent manner. This response was completely inhibited by the AT1R inhibitor candesartan but not by the AT2R blocker PD123319. In addition, Ang II-induced upregulation of MMP-2 was mediated by the activation of ERK1/2, whereas p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun N-terminal kinase (JNK) had no effect on this process. In conclusion, these results indicate that Ang II can increase the expression of MMP-2 via AT1 receptor and ERK1/2 signaling pathways in human ASMCs and suggest that antagonists of AT1R and ERK1/2 may be useful for treating TAAs.
机译:人类主动脉平滑肌细胞(人类ASMC)产生的血管紧张素II(Ang II)和活化基质金属蛋白酶2(MMP-2)水平升高,最近被认为与胸主动脉瘤(TAA)的发病机理有关。此外,血管紧张素II 1型受体(AT1R)介导的细胞外信号调节激酶(ERK)1/2激活也有助于马凡综合症中TAA的发展。但是,关于人类ASMC中Ang II和MMP-2表达之间关系的数据很少。因此,我们研究了Ang II对人ASMC中MMP-2表达的影响,并使用Western印迹法鉴定了Ang II受体和所涉及的细胞内信号通路。逆转录聚合酶链反应(RT-PCR)和免疫荧光数据表明,Ang II受体在人ASMC中表达。此外,Ang II在转录和翻译水平上均增加了Ang II 2型受体(AT2R)的表达,但未增加AT1R的表达。此外,蛋白质印迹显示Ang II以剂量和时间依赖性方式增加人ASMC中MMP-2的表达。该反应完全被AT1R抑制剂坎地沙坦抑制,但未被AT2R阻断剂PD123319抑制。此外,Ang II诱导的MMP-2上调是由ERK1 / 2的激活介导的,而p38丝裂原激活的蛋白激酶(p38 MAPK)和c-Jun N端激酶(JNK)对此过程没有影响。总之,这些结果表明,Ang II可以通过人ASMC中的AT1受体和ERK1 / 2信号通路增加MMP-2的表达,并暗示AT1R和ERK1 / 2的拮抗剂可用于治疗TAA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号